On the Horizon: Biologics and Nutrients for Neurotrophic Keratitis.

Eye Contact Lens

Ophthalmology, Memorial Ankara Hospital, Eye Clinic, Ankara, Turkey .

Published: March 2021

Neurotrophic keratitis (NK), a potentially sight-threatening corneal disease, still does not have a specific treatment. The reduction or complete loss of corneal sensation, the most important factor in its pathogenesis, is one of the most important factors that complicate the treatment of corneal wound healing. In addition, the visual outcome may be adversely affected because of aggressive stromal fibrosis in severe NK cases. Basically, the current management of NK aims to accelerate wound healing and prevent the progression. However, new therapeutic agents, particularly developed depending on cell type-specific healing mechanisms are required for better visual outcomes. In recent years, several studies have started to use new promising areas of translational research, including gene therapy, stem cell therapy, miRNA, and bioengineering. Evidence has emerged that future treatment strategies for NK will be designed by the results of these studies. In this review, it is aimed to summarize scientific data of new treatment modalities for NK.

Download full-text PDF

Source
http://dx.doi.org/10.1097/ICL.0000000000000757DOI Listing

Publication Analysis

Top Keywords

neurotrophic keratitis
8
wound healing
8
horizon biologics
4
biologics nutrients
4
nutrients neurotrophic
4
keratitis neurotrophic
4
keratitis sight-threatening
4
sight-threatening corneal
4
corneal disease
4
disease specific
4

Similar Publications

Introduction: Several cases of radio-induced neurotrophic keratitis had been observed after proton therapy delivering a mean corneal dose of ≥50 GyRBE. We conducted a prospective exploratory study to assess corneal sensitivity in subsequent patients undergoing proton therapy for cephalic extraocular tumors.

Material And Methods: Forty-three patients (85 eyes) treated with high-energy proton therapy were included in this prospective, single-center, observational cohort study.

View Article and Find Full Text PDF
Article Synopsis
  • Human umbilical cord blood serum (HUCBS) shows promise as an effective treatment for severe ocular surface disorders (OSDs) by speeding up healing and reducing inflammation, benefiting patients who haven't found relief through standard therapies.
  • A study of 49 patients with various severe OSDs was conducted at San Marco Hospital in Italy, categorizing patients based on causes like rheumatologic diseases and graft-versus-host disease.
  • Results indicated significant improvement in multiple assessments, including patient-reported outcomes and clinical evaluations, demonstrating the potential of HUCBS in treating resistant cases of OSDs.
View Article and Find Full Text PDF

Neuronal Intranuclear Inclusion Disease with a Corneal Disorder: A Case Report.

Medicina (Kaunas)

October 2024

Department of Ophthalmology and Visual Sciences, Graduate School of Biomedical Sciences, Nagasaki University, 1-7-1 Sakamoto, Nagasaki City 852-8501, Japan.

: Neuronal intranuclear inclusion disease (NIID) is a progressive neurodegenerative disorder characterized by the formation of intranuclear inclusions in cells. Adult-type NIID usually develops in elderly patients with various clinical manifestations and is sometimes accompanied by ocular symptoms. A case of adult-onset NIID with early and unique manifestations, including a progressive corneal defect and retinal changes, which are concerning at a young age, is reported.

View Article and Find Full Text PDF

Purpose: To review the existing literature to evaluate the utility of insulin eye drops as a treatment for neurotrophic-related epithelial defects.

Methods: A comprehensive literature search of Medline, Embase, and Web of Science and additional manual searches were conducted using relevant keywords. All articles published from January 2005 to January 2024 were examined.

View Article and Find Full Text PDF

Nerve growth factor treatment significantly improved visual acuity and non-visual outcomes and reversed the trend of visual decline in 1,476 patients with neurotrophic keratopathy within the IRIS Registry.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!